ライフサイエンスコーパス: naloxone

1 ex than lactic acid alone in the presence of naloxone.

2 eptibility to precipitation of withdrawal by naloxone.

3 ing negative-affective states in response to naloxone.

4 e independently more likely to be prescribed naloxone.

5 ) compared with patients who did not receive naloxone.

6 of minimizing risk of overdose is take-home naloxone.

7 receiving long-term opioids were prescribed naloxone.

8 as rapidly reversed by the opioid antagonist naloxone.

9 n G carriers is blocked by pretreatment with naloxone.

10 s, which express npr-17, did not response to naloxone.

11 ith pertussis toxin or the opioid antagonist naloxone.

12 ncement when co-administration with low dose naloxone.

13 -2200 was prevented by pre-administration of naloxone.

14 dence counseling; all received buprenorphine-naloxone.

15 ith pertussis toxin or the opioid antagonist naloxone.

16 e 2 success rates while taking buprenorphine-naloxone.

17 rrolidin-1-yl)methyl)phenoxy)benzamide], and naloxone.

18 without concurrent exposure to valsartan or naloxone.

19 ycemia, and this inhibition was prevented by naloxone.

20 ot reversed by a saturating concentration of naloxone.

21 ication recurs following quick metabolism of naloxone.

22 red from 0 to 60 min and at 300-360 min post naloxone.

23 nontransport after reversal of overdose with naloxone.

24 are facility after reversal of overdose with naloxone.

25 kg) preceded by either saline (Sal-Nalb) or naloxone 0.4 mg (Nalox-Nalb).

26 nous administration of the opioid antagonist naloxone (0.15 mg/kg bolus + 0.1 mg/kg/h infusion) or sa

27 Preblocking with naloxone (1 mg/kg) or LY2795050 (0.2 mg/kg) produced 84%

28 Pretreatment with naloxone (1 mg/kg, intravenously) resulted in a uniform

29 Pretreatment with naloxone (1 mg/kg, intravenously) resulted in a uniform

30 , the nonspecific opioid receptor antagonist naloxone (1 mum) enhanced MF transmission but there was

31 e preferential mu-opioid receptor antagonist naloxone (1, 10, or 30 mg/kg), decreased selective aggre

32 ific effect blocked by the opioid antagonist naloxone (10 muM).

33 d-release naltrexone and 79 to buprenorphine-naloxone; 105 (66.0%) completed the trial.

34 for 16 weeks (starting dose oxycodone 5 mg, naloxone 2.5 mg, twice daily).

35 al found that lower-concentration intranasal naloxone (2 mg/5 mL) was less effective than intramuscul

36 cacy between higher-concentration intranasal naloxone (2 mg/mL) and intramuscular naloxone, and 1 tri

37 Higher-concentration intranasal naloxone (2 mg/mL) seems to have efficacy similar to tha

38 s were pretreated with the opioid antagonist naloxone (3 mg/kg; intraperitoneally).

39 injury, the effects of the opioid antagonist naloxone (3 mg/kg; IP) on retinal neuroprotection induce

40 ither daily oral flexible dose buprenorphine-naloxone, 4 to 24 mg/d, or extended-release naltrexone h

41 tions were randomized in a blinded manner to naloxone 8 mg or saline placebo if lung were being consi

42 is analgesia is blocked by pretreatment with naloxone, a mu-opioid antagonist.

43 Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are cur

44 can be interrupted by the administration of naloxone, a safe and effective opiate antagonist that ca

45 responses were enhanced by intrapericardial naloxone, a specific opioid receptor antagonist.

46 nd postnatal mortality, was conferred by (+)-naloxone administration after intrauterine administratio

47 emporal resolution following intranasal (IN) naloxone administration to healthy volunteers in the abs

48 ized trials that compared different doses of naloxone, administration routes, or transport versus non

49 Injection of either Leu-Enk or naloxone alone significantly increased the testicular in

50 (+)-Naloxone also reduced opioid (remifentanil) self-adminis

51 Naloxone ameliorated the clinical progression and severi

52 emonstrated that the opioid receptor blocker naloxone ameliorates HAAF.

53 cts of norfentanyl, the main metabolite, and naloxone, an antidote used in fentanyl overdose, were al

54 Naloxone, an opioid antagonist, restores HPA axis respon

55 The role of naloxone, an opioid receptor antagonist, on microglial i

56 onian rats; this effect was fully blocked by naloxone, an opioid receptor antagonist.

57 loxone methiodide (a peripherally restricted naloxone analog) and by local administration at the infl

58 We report the assessment of (+)-naloxone and (+)-naltrexone on the acute dopaminergic ef

59 mental conditions, the TLR4 antagonists, (+)-naloxone and (+)-naltrexone, did not specifically block

60 ion was obtained at the highest doses of (+)-naloxone and (+)-naltrexone, those doses also attenuated

61 Naloxone and a combination of mu and delta opioid recept

62 -dependent migration effect was inhibited by naloxone and confirmed to be mu-opioid receptor-dependen

63 Buprenorphine-naloxone and extended-release naltrexone.

64 gesia was reversed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restric

65 their reversal by the pan-opioid antagonists naloxone and naltrexone and evidence for a therapeutic b

66 Recently, the (+)-enantiomers of naloxone and naltrexone, TLR4 antagonists, have been rep

67 and administration of the opioid antagonist naloxone and placebo saline.

68 n silico and biophysical data to support (+)-naloxone and remifentanil binding to TLR4/MD2.

69 and both the nonselective opioid antagonist naloxone and the kappa-selective blocker norbinaltorphim

70 santness reductions between the meditation + naloxone and the meditation + saline groups.

71 Blocking studies were performed with naloxone and the selective KOR antagonists LY2795050 and

72 time in opioid dose among those who received naloxone and those who did not (IRR, 1.03 [CI, 0.91 to 1

73 s, as indicated by its sensitivity to spinal naloxone and to the selective mu1-opioid receptor antago

74 y of opioid agonist treatment (buprenorphine-naloxone) and nonpharmacologic therapies (eg, CBT) for o

75 ranasal naloxone (2 mg/mL) and intramuscular naloxone, and 1 trial found that lower-concentration int

76 Using oxycodone, naloxone, and an IgG-sized antibody as relevant model dr

77 l10 in fetal membranes was suppressed by (+)-naloxone, and cytokine expression in the placenta, and u

78 (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2)), naloxone, and naltrexone behave like partial agonists.

79 eraction with the opioid receptor antagonist naloxone, and two-way analgesic cross-tolerance with mor

80 Tapentadol and oxycodone-naloxone are found to exhibit better tolerability charac

81 plasma concentrations peaked at ~20 min post naloxone, associated with slightly delayed development o

82 ignificantly lesser withdrawal symptoms than naloxone at similar doses.

83 nd retrospective studies have suggested that naloxone attenuates neurogenic pulmonary edema and rever

84 This effect was blocked with naloxone before each mating session; thus, VTA dopamine

85 [(3)H]Naloxone binding in membranes of the thalamus showed no

86 n after a 50 mV depolarization, fentanyl and naloxone blocked hERG current (I(hERG)) with IC(50) valu

87 gonist, carboxynitroveratryl-naloxone (caged naloxone), blocked the current induced by a series of ag

88 nistration of the opioid receptor antagonist naloxone blocks acute CB1R-induced feeding.

89 Buprenorphine-naloxone (BUP) is an effective treatment of opioid depen

90 oid antagonist, and sublingual buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are pharmac

91 ncountered by patients seeking buprenorphine-naloxone ("buprenorphine") treatment.

92 of a subset of these genes was preserved by naloxone but not valsartan.

93 ocorticoid secretion, a failure prevented by naloxone but not valsartan.

94 /5 mL) was less effective than intramuscular naloxone but was associated with decreased risk for agit

95 this series was found to be more potent than naloxone but weaker than 1.

96 of a caged antagonist, carboxynitroveratryl-naloxone (caged naloxone), blocked the current induced b

97 Naloxone can be coprescribed to primary care patients pr

98 signaling with the novel TLR4 antagonist (+)-naloxone can suppress the inflammatory cascade of preter

99 Carboxynitroveratryl-naloxone (CNV-NLX), a caged analog of the competitive op

100 lar, middle cingulate cortices, and putamen; naloxone co-admistration reduced all connectivity to non

101 Tapentadol was followed by oxycodone-naloxone combination in providing better tolerability an

102 d to predict brain MOR occupancy from plasma naloxone concentrations.

103 atment of animals with the opioid antagonist naloxone, confirming opioid receptor-mediated analgesia.

104 Naloxone decreased the surface/intracellular ratio and s

105 In mice, (+)-naloxone did not decrease drinking-in-the-dark and only

106 Naloxone did not prevent the initial experience-induced

107 ethiodide, a membrane impenetrable analog of naloxone, did not affect the NSC differentiation.

108 in 37% of iterations and the combination of naloxone distribution and linkage to addiction treatment

109 health benefit for a particular budget) were naloxone distribution combined with linkage to addiction

110 ge to addiction treatment (cost saving), and naloxone distribution combined with PrEP and linkage to

111 Naloxone distribution for lay administration.

112 Naloxone distribution increased costs by $53 (CI, $3 to

113 ctiveness ratio (ICER) of $323 per QALY, and naloxone distribution plus linkage to addiction treatmen

114 itional intervention, naloxone distribution, naloxone distribution plus linkage to addiction treatmen

115 atment, naloxone distribution plus PrEP, and naloxone distribution plus linkage to addiction treatmen

116 ibution plus linkage to addiction treatment, naloxone distribution plus PrEP, and naloxone distributi

117 ompared with no additional intervention, the naloxone distribution strategy yielded an incremental co

118 INTERPRETATION: Naloxone distribution through syringe service programmes

119 Naloxone distribution to heroin users is likely to reduc

120 Naloxone distribution was cost-effective in all determin

121 Combining naloxone distribution with linkage to addiction treatmen

122 tive strategies: no additional intervention, naloxone distribution, naloxone distribution plus linkag

123 tic sensitivity analysis, the combination of naloxone distribution, PrEP, and linkage to addiction tr

124 A strategy that combines naloxone distribution, PrEP, and linkage to addiction tr

125 s, 6% of overdose deaths were prevented with naloxone distribution; 1 death was prevented for every 2

126 Naloxone does not improve oxygenation more than placebo

127 Thus, OR blockade with naloxone during antecedent exercise prevents the develop

128 reward and memory in male rats treated with naloxone during mating experience, either systemically o

129 xone treatment; if tapered off buprenorphine-naloxone, even after 12 weeks of treatment, the likeliho

130 The rapid onset of brain MOR occupancy by IN naloxone, evidenced by the rapid onset of its action in

131 Twelve-day-old pups given naloxone (Experiment 1A) or baclofen (Experiment 1B) bef

132 action was found to be higher with oxycodone-naloxone followed by fentanyl and tapentadol.

133 coverage of buprenorphine and buprenorphine-naloxone for opioid use disorder in 2007, 2012, and 2018

134 ve efficacy similar to that of intramuscular naloxone for reversal of opioid overdose, with no differ

135 e group was noninferior to the buprenorphine-naloxone group (difference, -0.1; with 95% CI, -0.2 to 0

136 Drug development strategies involving naloxone have been initiated to reduce peripheral opioid

137 was found to be ~40-fold less permeable than naloxone-HCl across the blood-brain barrier, thus acting

138 sensors in freely moving rats to examine how naloxone-HCl and naloxone-methiodide, the latter which i

139 Similar to naloxone-HCl, naloxone-methiodide at a relatively low do

140 ve as daily buprenorphine hydrochloride with naloxone hydrochloride in maintaining abstinence from he

141 .) but not by the opioid receptor antagonist naloxone (i.p.).

142 randomized to receive intravenous saline or naloxone immediately before sham and real left DLPFC rTM

143 s of FeTMPyP(5+) were abrogated by intra-RVM naloxone, implicating potential interplay between PN and

144 is based on the local antagonist activity of naloxone in intestinal opioid receptors and the negligib

145 naltrexone was as effective as buprenorphine-naloxone in maintaining short-term abstinence from heroi

146 and (3) injection of the TLR4 antagonist (+)-naloxone in mice.

147 less severe opioid withdrawal symptoms than naloxone in morphine-dependent mice.

148 uch less significant withdrawal effects than naloxone in morphine-pelleted mice.

149 Concentrations of naloxone in plasma and MOR availability (relative to pla

150 Providing naloxone in primary care settings may have ancillary ben

151 In contrast to its effects on low singers, naloxone in the POM of high singers dose dependently dec

152 isomer of the opioid receptor antagonist (-)-naloxone, in infection-associated preterm birth.

153 c shell of morphine-dependent rats prevented naloxone-induced conditioned place aversions and decreas

154 tagonist of GluA2-lacking AMPARs, attenuated naloxone-induced decreases in sensitivity to brain stimu

155 Conversely, naloxone infused into the basolateral amygdala blocked f

156 -min hyperinsulinemic-euglycemic clamps plus naloxone infusion (control); 2) two 90-min hyperinsuline

157 c clamps with exercise at 60% Vo(2max), plus naloxone infusion (N+); or 3) same protocol as in the N+

158 However, naloxone infusion failed to reverse meditation-induced a

159 ge of NSC differentiation, morphine, but not naloxone, inhibited neurogenesis via traditional recepto

160 ked opioid receptor activity in the POM with naloxone injections and found that this increased both s

161 These effects were naloxone insensitive and thus are not opioid receptor me

162 to demonstrate that direct administration of naloxone into the POM influences sexually motivated song

163 stered with a mu-opioid receptor antagonist, naloxone, invoked a supralinear enhancement of prolonged

164 placebo-controlled trial to evaluate whether naloxone is able to improve oxygenation in BD donors wit

165 Acute MWD induced place aversion occurs when naloxone is administered 24 h following a single exposur

166 Naloxone is an opioid antagonist used to reverse opioid

167 Naloxone is effective for reversing opioid overdose, but

168 While naloxone is known for its short half-life, we found the

169 Buprenorphine-naloxone is preferred to extended-release naltrexone as

170 ibution; 1 death was prevented for every 227 naloxone kits distributed (95% CI, 71 to 716).

171 rved BP(ND) was low, although treatment with naloxone leads to a marked decrease in specific binding,

172 compared in opioid-dependent, buprenorphine-naloxone-maintained, human immunodeficiency virus (HIV)-

173 IN naloxone may have therapeutic utility in various addicti

174 ersed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restricted naloxone

175 ous administration, which was antagonized by naloxone methiodide demonstrating activation of peripher

176 However, naloxone methiodide, a membrane impenetrable analog of n

177 of naloxone was found in brain tissue after naloxone-methiodide administration, potentially influenc

178 Similar to naloxone-HCl, naloxone-methiodide at a relatively low dose (2 mg/kg) f

179 Therefore, we examined the effects of naloxone-methiodide at a very low dose (0.2 mg/kg; at wh

180 As measured by mass spectrometry, naloxone-methiodide was found to be ~40-fold less permea

181 moving rats to examine how naloxone-HCl and naloxone-methiodide, the latter which is commonly believ

182 Naloxone modulates microglia accumulation and activation

183 9 lung-eligible BD donors were randomized to naloxone (n = 98) or placebo (n = 101).

184 nefit of concurrent administration of OT and naloxone (NAL) to robustly modulate social behavior.

185 ration of the nonopioid, unnatural isomer of naloxone, (+)-naloxone (rats), or two independent geneti

186 hans, and the classic mu opioid antagonists, naloxone, naltrexone, and nalmefene.

187 nguage placebo-controlled clinical trials of naloxone, naltrexone, nalmefene, and buprenorphine in pa

188 The opioid antagonists naloxone/naltrexone are involved in improving learning a

189 In vitro prolonged naloxone/naltrexone exposure significantly increased syn

190 We investigated the effect of naloxone/naltrexone on hippocampal alpha-amino-3-hydroxy

191 To measure naloxone/naltrexone-regulated AMPAR trafficking, pHluori

192 ecipitated by subcutaneous administration of naloxone (NLX) (2 mg/kg).

193 ays for entry of the nonselective antagonist naloxone (NLX) from the water environment into the well-

194 Meanwhile, intrathecal pretreatment with naloxone, non-selective opioid receptor antagonist, did

195 the effect of nalbuphine or nalbuphine plus naloxone on activity in brain regions that may explain t

196 The authors evaluated the effects of naloxone on Ccl2(-/-)/Cx3cr1(-/-) (DKO) mice, a murine m

197 ephalin (Met-Enk), and the opioid antagonist naloxone on gonad development in the Eastern lubber gras

198 exone showed noninferiority to buprenorphine-naloxone on group proportion of total number of opioid-n

199 The potential therapeutic effects of naloxone on retinal degeneration, including AMD, warrant

200 comes were proportion of patients prescribed naloxone, opioid-related emergency department (ED) visit

201 Pretreatments with (+)-naloxone or (+)-naltrexone did not attenuate, and under

202 Blood ethanol levels were not affected by naloxone or baclofen (Experiment 2).

203 Respiratory compromise was defined as use of naloxone or flumazenil, nonmechanical or cardiopulmonary

204 re given daily intraperitoneal injections of naloxone or PBS for 2 months.

205 d by pretreatment with the opioid antagonist naloxone or the Src kinase inhibitor 4-amino-5-(4-chloro

206 (OR) 1.22, 95% CI, 1.00-1.49] and receipt of naloxone (OR 1.58, 95% CI, 1.11-2.26).

207 onist-antagonist combinations (buprenorphine-naloxone), or neither agonists nor antagonists within th

208 esic efficacy of prolonged-release oxycodone-naloxone (OXN PR) in patients with Parkinson's disease a

209 ommonly used anesthetics nor with methadone, naloxone, oxycodone, or heroin.

210 show a decline in avoidance of the formerly naloxone-paired chamber with increasing numbers of extin

211 s and the negligible oral bioavailability of naloxone, particularly in a prolonged-release formulatio

212 Naloxone plasma concentrations peaked at ~20 min post na

213 is highlights the need to increase access to naloxone, possibly through regulatory approval for over-

214 ade of morphine binding to PAG TLR4 with (+)-naloxone potentiated morphine antinociception significan

215 Application of the opioid antagonist naloxone potentiates noxious peripheral input into the s

216 ents, like intestinal transit inhibition and naloxone-precipitated behavioral signs of opiate withdra

217 nociceptive effects of oxycodone and reduced naloxone-precipitated conditioned place aversion in rats

218 In addition, JZL184 or PF-3845 blocked naloxone-precipitated hypersecretion in morphine-depende

219 e exhibited a trend (P = 0.055) toward fewer naloxone-precipitated jumps compared with CB2KO mice.

220 y tying enhanced cAMP-driven GABA release to naloxone-precipitated morphine withdrawal in the VTA.

221 Following naloxone-precipitated morphine withdrawal, NE release an

222 he basolateral amygdala, interfered with the naloxone-precipitated MWD induced place aversion.

223 fatty acid amide hydrolase (FAAH) attenuates naloxone-precipitated opioid withdrawal signs in mice vi

224 ted continuous morphine exposure with either naloxone-precipitated or spontaneous withdrawal.

225 eir drug intake over time and exhibited both naloxone-precipitated somatic signs of opioid withdrawal

226 sufentanil vapor), LgA rats again developed naloxone-precipitated somatic signs of withdrawal and sp

227 OW-CPA through pairings of one chamber with naloxone-precipitated withdrawal and the other chamber w

228 overflow during acute morphine exposure and naloxone-precipitated withdrawal in two regions associat

229 Chronic morphine exposure and naloxone-precipitated withdrawal increase activity of sp

230 ncomitantly promotes analgesic tolerance and naloxone-precipitated withdrawal, whereas downregulation

231 d clinic staff were trained and supported in naloxone prescribing.

232 Patients who received a naloxone prescription had 47% fewer opioid-related ED vi

233 d with a reversal of this reprogramming, and naloxone preserves some responses to hypoglycemia by pre

234 Naloxone pretreatment largely abolished rTMS-induced ana

235 Naloxone pretreatment to nalbuphine produced changes in

236 and this protective response was reversed by naloxone pretreatment.

237 Treatment with (+)-naloxone prevented preterm delivery and alleviated fetal

238 Furthermore, mindfulness meditation during naloxone produced significantly greater reductions in pa

239 was adequate for use in the development of a naloxone product intended for over-the-counter sales.

240 ed to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose.

241 Therefore, morphine and naloxone promote neurogenesis in a receptor-independent

242 nonopioid, unnatural isomer of naloxone, (+)-naloxone (rats), or two independent genetic knock-outs o

243 In addition, morphine and naloxone respectively stimulated and inhibited feeding i

244 d evoke a pressor reflex), endomorphin-2 and naloxone resulted in a significantly greater pressor res

245 The non-selective opioid antagonist, naloxone, returned the water content nearly back to orig

246 Pretreatment with naloxone reversed both the functional and structural ret

247 Inhibition of the PVN with naloxone reversed the EA-inhibition.

248 Naloxone reversed the morphine-induced suppression of TN

249 synaptic release of opioid peptides and to a naloxone-reversible hypoalgesic/antiallodynic phenotype.

250 mic administration of the opiate antagonist, naloxone, robustly increased LC discharge rate in a mann

251 To synthesize evidence on 1) the effects of naloxone route of administration and dosing for suspecte

252 Nontransport after reversal of overdose with naloxone seems to be associated with a low rate of serio

253 Co-administration/pretreatment of naloxone selectively blocked activity in pulvinar, pons

254 aracteristics of both analgesia and algesia; naloxone selectively blocks activity in areas associated

255 chronic pain, intra-RVM FeTMPyP(5+) produced naloxone-sensitive reversal of mechanical allodynia in r

256 The antiallodynic effect of TGF-beta1 was naloxone-sensitive.

257 Naloxone significantly reduces the progress of retinal l

258 ment (phase 1) included 2-week buprenorphine-naloxone stabilization, 2-week taper, and 8-week postmed

259 t buprenorphine or with either naltrexone or naloxone, structurally related MOR antagonists.

260 NX was daily self-administered buprenorphine-naloxone sublingual film (Suboxone; Indivior).

261 up to 2 weeks' treatment with buprenorphine-naloxone sublingual film.

262 tment with either methadone or buprenorphine/naloxone (Suboxone) over a 24-week open-label clinical t

263 reversible by intrathecal administration of naloxone, suggesting an opioid-mediated mechanism; pharm

264 ferential mu-opioid receptor inverse agonist naloxone, suggesting the participation of mu-opioid rece

265 fter induction with sublingual buprenorphine-naloxone tablets, patients received either 4 buprenorphi

266 s 8 weeks after completing the buprenorphine-naloxone taper (phase 2, week 24) dropped to 8.6% (31 of

267 were more common while taking buprenorphine-naloxone than 8 weeks after taper (49.2% [177 of 360] vs

268 rsed by treatment with the opiate antagonist naloxone, the beta-receptor agonist metaproterenol, or t

269 a novel small molecule TLR4 antagonist, (+)-naloxone, the non-opioid isomer of the opioid receptor a

270 iception comparable to the opioid antagonist naloxone, the standard of care drug for treating opioid

271 analogue of 14,15-EET, the opioid antagonist naloxone, the thromboxane mimetic U46619, or the cannabi

272 When advised to offer naloxone to all patients receiving opioids, providers ma

273 ld of $100 000 per QALY showed buprenorphine-naloxone to be preferable to extended-release naltrexone

274 The abilities of morphine and naloxone to facilitate neurogenesis were also observed i

275 ina in DKO mice was significantly reduced in naloxone-treated animals compared with control untreated

276 nscripts and A2E were significantly lower in naloxone-treated DKO animals and cultured microglial cel

277 mes in phase 2 during extended buprenorphine-naloxone treatment (week 12), with no difference between

278 However, naloxone treatment attenuated the longer-term expression

279 emia, but not after antecedent hypoglycemia; naloxone treatment prevented this failure.

280 d for rescue use of sublingual buprenorphine-naloxone treatment was exceeded.

281 ed phase 2: extended (12-week) buprenorphine-naloxone treatment, 4-week taper, and 8-week postmedicat

282 in nontransported patients after successful naloxone treatment.

283 ly to reduce opioid use during buprenorphine-naloxone treatment; if tapered off buprenorphine-naloxon

284 A B agonist (baclofen) or opioid antagonist (naloxone) treatments.

285 e (A2D2) that can administer a large dose of naloxone upon detection of overdose-induced respiratory

286 sociations of receipt of gabapentinoids with naloxone use after surgery, non-invasive ventilation (NI

287 t was associated with higher odds of NIV and naloxone use after surgery.

288 the instructions in the drug facts label for naloxone use and came close on two others.

289 nation (median improvement in PFR of 81 with naloxone versus 80 with saline, P = 0.68), with 37 (39%)

290 selectivity, a low but detectable amount of naloxone was found in brain tissue after naloxone-methio

291 rio" where overdose was rarely witnessed and naloxone was rarely used, minimally effective, and expen

292 dide at a very low dose (0.2 mg/kg; at which naloxone was undetectable in brain tissue) and found tha

293 Conversely, the antagonist, naloxone, was predicted to have prosurvival effects, pri

294 l symptoms following injections of 1.0 mg/kg naloxone were compared in active and inactive male and f

295 When two opioids, morphine and naloxone, were used during the early stage of NSC differ

296 in the absence of morphine by administering naloxone with an alpha2 antagonist.

297 Surprisingly, co-injection of naloxone with either enkephalin enhanced the effect asso

298 ugh evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating o

299 ational and state rates of co-prescribing of naloxone with opioids and benzodiazepines in 2016-2017.

300 demonstrate a significant interaction of (+)-naloxone with subjective effects of cocaine.